New aspects for the therapeutic stratification of urological tumor patients


Molecular Tumor Board (MTB)

  • Discussion and presentation of patients with advanced tumor diseases
  • Interdisciplinary, 2-weekly
  • Urological case registrations via Ms. Klevenow
  • Further important information for external registrants can be found here: Claudia von Schilling Center

Individualized therapies through comprehensive molecular analyses ("next-generation sequencing" NGS)

  • Prostate cancer: AR-V7 splice variant, BRCA1/2 mutation, MSI, ATM, FANCA, PALB2, etc.
  • Urothelial carcinoma: ctDNA, PD-L1 immune status, FGFR alterations, p53 mutation
  • Renal cell carcinoma: PD-L1 immune status, molecular classification of various subtypes of NCC (e.g. MET mutation, VHL, FH, etc.)
  • Penile carcinoma: Ki67, p16, miRNA-1: indication for lymphadenectomy, molecular genetic analyses: EGFR, HER status, HPV, PD-L1, etc.

Targeted therapies in the context of studies

Genetic counseling

  • Patients and their relatives can receive individual genetic counseling from the local Institute of Human Genetics if they have a genetic mutation.